

Publikasjoner SESAM 2019

I 2019 hadde SESAM 46 publikasjoner i ulike tidsskrifter – 9 er nivå 2 publikasjoner

1. Andreassen Ø, Brønnick K, Njå AL, Furulund E, Nesvåg S.

The Effect of High-Intensity Interval/Circuit Training on Cognitive Functioning and Quality of Life During Recovery From Substance Abuse Disorder. A Study Protocol. *Frontiers in Psychology*, 15;10:2564. Nivå 2

2. Ashraf A, Stosnach H, Parkes HG, Hye A, Powell J, Aarsland D, So PW.

Pattern of Altered Plasma Elemental Phosphorus, Calcium, Selenium, Iron and Copper in Alzheimers Disease. *Scientific Reports*, 28;9(1):3147. Nivå 1

3. Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A.

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. *Acta Neuropathologica Communications*. 2019 Jan 9;7(1):5. Nivå 1

4. Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. *Science Advances*, 2019 Feb 6;5(2):eaau7220. Nivå 1

5. Bencze J, Szarka M, Bencs V, Szabó RN, Smajda M, Aarsland D, Hortobágyi T.

Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. *Scientific Reports*, 20;9(1):17222. Nivå 1

6. Bergland AK, Soennesyn H, Dalen I, Rodriguez-Mateos A, Berge RK, Giil LM, Rajendran L, Siow R, Tassotti M, Larsen AI, Aarsland D.

Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia - A Pilot Study. *Frontiers in Genetics*, 11;10:536. Nivå 1

7. Bjerkreim AT, Khanevski A, Thomassen L, Selvik HA, Waje-Andreassen U, Næss H, Logallo N.

Five-year readmission and mortality differ by ischemic stroke subtype. *Journal of the Neurological Sciences*, 15;403:31-37. Nivå 1

8. Bjerkreim AT, Naess H, Khanevski AN, Thomassen L, Waje-Andreassen U, Logallo N.

One-year versus five-year hospital readmission after ischemic stroke and TIA. *BMC Neurology*. 2019 Jan 29;19(1):15. Nivå 1

9. Borda MG, Castellanos-Perilla N, Aarsland D.

Asociación entre pérdida del apetito y niveles de albúmina en adultos mayores con enfermedad de Alzheimer leve. [Relationship between loss of appetite and albumin levels in older adults with mild Alzheimer's disease]. *Revista Española de Geriatria y Gerontología*. Nivå 1

10. Borda MG, Patino-Hernandez D, Cano-Gutiérrez CA, Celis-Preciado CA, Pérez-Zepeda MU.

Sarcopenia, lung disease and mortality: a secondary analysis of the CRELES study. *Geriatrics, Gerontology and Aging*, 36-38.

11. Borda MG., Pérez-Zepeda MU, Camilo Gómez-Arteaga MD, Ana María Pardo-Amaya MD, Chavarro-Carvajal D, Carlos Cano-Gutiérrez MD.

Asociación entre fuerza de prensión y comorbilidades: Estudio Sabe, Ecuador, 2009. *Revista Ciencias de la Salud*, 17(2), 309-220.

12. Borda MG, Pérez-Zepeda MU, Samper-Ternent R, Gómez RC, Avila-Funes JA, Cano-Gutierrez CA.

The Influence of Lifestyle Behaviors on the Incidence of Frailty. *The Journal of Frailty & Aging*, 1-6. Nivå 1

13. Borda MG, Reyes-Ortiz CA, Heredia RA, Castellanos-Perilla N, Ayala Copete AM, Soennesyn H, Cano-Gutierrez CA, Perez-Zepeda MU.

Association between self-reported hearing impairment, use of a hearing aid and performance of instrumental activities of daily living. *Archives of Gerontology and Geriatrics*, 6;83:101-105. Nivå 1

14. Borda MG, Santacruz JM, Aarsland D, Camargo-Casas S, Cano-Gutierrez CA, Suárez-Monsalve S, Campos-Fajardo S, Pérez-Zepeda MU.

Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure. *European geriatric medicine*, 10(3), 413-420. Nivå 1

15. Borda MG, Soennesyn H, Steves CJ, Vik-Mo AO, Pérez-Zepeda MU, Aarsland D.

Frailty in Older Adults with Mild Dementia: Dementia with Lewy Bodies and Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders Extra*, 9(1), 176-183. Nivå 1

16. Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, Megalogeni M, Corbett A, Aarsland D, Ballard C.

Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. *The American journal of geriatric psychiatry*, 27(8):823-834. Nivå 1

17. Creese B, Vassos E, Bergh S, Athanasiu L, Johar I, Rongve A, Medbøen IT, Vasconcelos Da Silva M, Aakhus E, Andersen F, Bettella F, Braekhus A, Djurovic S, Paroni G, Proitsi P, Saltvedt I, Seripa D, Stordal E, Fladby T, Aarsland D, Andreassen OA, Ballard C, Selbaek G; AddNeuroMed consortium and the Alzheimer's Disease Neuroimaging Initiative.

Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. *Translational Psychiatry*, 22;9(1):273. Nivå 1

18. Cserép C, Pósfai B, Lénárt N, Fekete R, László ZI, Lele Z, Orsolits B, Molnár G, Heindl S, Schwarcz AD, Ujvári K, Környei Z, Tóth K, Szabadits E, Sperlág B, Baranyi M, Csiba L, Hortobágyi T, Maglóczky Z, Martinecz B, Szabó G, Erdélyi F, Szipőcs R, Tamkun MM, Gesierich B, Duering M, Katona I, Liesz A, Tamás G, Dénes Á.

Microglia monitor and protect neuronal function via specialized somatic purinergic junctions. *Science*. [Epub ahead of print] Nivå 2

19. Dave S, Weintraub D, Aarsland D, Ffytche DH.

Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. *Movement Disorders Clinical Practice*, 7(1), 32-36. Nivå 1

20. Fossey J, Garrod L, Tolbol Froiland C, Ballard C, Lawrence V, Testad I.

What influences the sustainability of an effective psychosocial intervention for people with dementia living in care homes? A 9 to 12-month follow-up of the perceptions of staff in care homes involved in

the WHELD randomised controlled trial. *International Journal of Geriatric Psychiatry*, 34(5):674-682. Nivå 1

21. Førland MG, Tysnes OB, Aarsland D, Maple-Grødem J, Pedersen KF, Alves G, Lange J.
The value of cerebrospinal fluid α -synuclein and the tau/ α -synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. *European Journal of Neurology*, 27(1):43-50. Nivå 2

22. Giil LM, Solvang SH, Giil MM, Hellton KH, Skogseth RE, Vik-Mo AO, Hortobágyi T, Aarsland D, Nordrehaug JE.
Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. *Journal of Alzheimer's Disease*, 68(1):239-253. Nivå 1

23. Gómez C, Borda MG, Pérez MU, Tella-Vega P, Cano-Gutiérrez CA.
Asociación entre uso de inhibidores de bomba de protones y deterioro cognitivo en adultos mayores. *Universitas Médica*, 60(1).

24. Huber M, Beyer L, Prix C, Schönecker S, Palleis C, Rauchmann BS, Morbelli S, Chincarini A, Bruffaerts R, Vandenberghe R, Van Laere K, Kramberger MG, Trost M, Grmek M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Vöglein J, Schnabel J, Unterrainer M, Perneczky R, Pogarell O, Buerger K, Catak C, Bartenstein P, Cumming P, Ewers M, Danek A, Levin J, Aarsland D, Nobili F, Rominger A, Brendel M.
Metabolic correlates of dopaminergic loss in dementia with lewy bodies. *Movement Disorders*. [Epub ahead of print] Nivå 1

25. Husebø BS, Ballard C, Aarsland D, Selbaek G, Slettebo DD, Gulla C, Aasmul I, Habiger T, Elvegaard T, Testad I, Flo E.
The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). *Journal of the American Medical Directors Association*. [Epub ahead of print] Nivå 1

26. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D.
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics*, 51(3):404-413. Nivå 2

27. Khanevski AN, Bjerkreim AT, Novotny V, Naess H, Thomassen L, Logallo N, Kvistad CE; NOR-STROKE study group.
Recurrent ischemic stroke: Incidence, predictors, and impact on mortality. *Acta Neurologica Scandinavica*. [Epub ahead of print] Nivå 1

28. Kvalø SE, Dyrstad SM, Bru E, Brønneck K.
Relationship between aerobic fitness and academic performance: the mediational role of executive function. *The Journal of Sports Medicine and Physical Fitness*, 59(8):1397-1404. Nivå 1

- 29. Kvistad CE, Novotny V, Kurz MW, Rønning OM, Thommessen B, Carlsson M, Waje-Andreassen U, Næss H, Thomassen L, Logallo N.**
Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. *Stroke*, 50(5):1279-1281. Nivå 2
- 30. Mendonça CF, Kuras M, Nogueira FCS, Plá I, Hortobágyi T, Csiba L, Palkovits M, Renner É, Döme P, Marko-Varga G, Domont GB, Rezeli M.**
Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. *Neurobiology of Disease*, 130:104509. Nivå 1
- 31. Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Aarsland D, Nobili F.**
Metabolic patterns across core features in dementia with lewy bodies. *Annals of Neurology*, 85(5):715-725. Nivå 2
- 32. Morsund ÅH, Ellekjær H, Gramstad A, Reiestad MT, Midgard R, Sando SB, Jonsbu E, Næss H.**
Cognitive and Emotional Impairment after Minor Stroke and Non-ST-Elevation Myocardial Infarction (NSTEMI): A Prevalence Study. *Stroke Research and Treatment*, 1;2019:2527384. Nivå 1
- 33. Morsund ÅH, Ellekjaer H, Gramstad A, Reiestad MT, Midgard R, Sando SB, Jonsbu E, Naess H.**
The development of cognitive and emotional impairment after a minor stroke: A longitudinal study. *Acta Neurologica Scandinavica*, 140(4):281-289. Nivå 1
- 34. Mueller C, Soysal P, Rongve A, Isik AT, Thompson T, Maggi S, Smith L, Basso C, Stewart R, Ballard C, O'Brien JT, Aarsland D, Stubbs B, Veronese N.**
Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. *Ageing Research Reviews*, 50:72-80. Nivå 1
- 35. Naess H, Logallo N, Waje-Andreassen U, Thomassen L, Kvistad CE.**
U-shaped relationship between hemoglobin level and severity of ischemic stroke. *Acta Neurologica Scandinavica*. [Epub ahead of print] Nivå 1
- 36. Nawaz B, Eide GE, Fromm A, Øygarden H, Sand KM, Thomassen L, Næss H, Waje-Andreassen U.**
Young ischaemic stroke incidence and demographic characteristics - The Norwegian stroke in the young study - A three-generation research program. *European Stroke Journal*, 4(4):347-354. Nivå 1
- 37. Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, Torsetnes SB, Grøntvedt GR, Waterloo KK, Aarsland D, Nilsson LNG, Fladby T.**
Glial activation and inflammation along the Alzheimer's disease continuum. *Journal of Neuroinflammation*, 21;16(1):46. Nivå 1
- 38. Novotny V, Khanevski AN, Bjerkreim AT, Kvistad CE, Fromm A, Waje-Andreassen U, Næss H, Thomassen L, Logallo N.**
Short-Term Outcome and In-Hospital Complications After Acute Cerebral Infarcts in Multiple Arterial Territories. *Stroke*, 50(12):3625-3627. Nivå 2
- 39. Oppedal K, Borda MG, Ferreira D, Westman E, Aarsland D; European DLB Consortium.**
European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative. *Neurodegenerative Disease Management*. 2019 Oct;9(5):247-250. Nivå 1

40. Osland Vik-Mo A, Melvaer Giil L, Germán Borda M, Ballard C, Aarsland D.

The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. *The British Journal of Psychiatry*. 2019. Nivå 2

41. Patil KS, Basak I, Dalen I, Hoedt E, Lange J, Lunde KA, Liu Y, Tysnes OB, Forsgren L, Aarsland D, Neubert TA, Larsen JP, Alves G, Møller SG.

Combinatory microRNA serum signatures as classifiers of Parkinson's disease. *Parkinsonism & Related Disorders*. [Epub ahead of print] Nivå 1

42. Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA.

GBA and APOE $\epsilon 4$ associate with sporadic dementia with Lewy bodies in European genome wide association study. *Scientific Reports*, 7;9(1):7013. Nivå 1

43. Rønning OM, Logallo N, Thommessen B, Tobro H, Novotny V, Kvistad CE, Aamodt AH, Næss H, Waje-Andreassen U, Thomassen L.

Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. *Stroke*. 50(2):498-500. Nivå 2

44. Terum TM, Testad I, Rongve A, Aarsland D, Svendsboe E, Andersen JR.

The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress. *International Journal of Geriatric Psychiatry*. [Epub ahead of print] Nivå 1

45. Testad I, Kajander M, Froiland CT, Corbett A, Gjestsen M, Anderson JG.

Nutritional interventions for persons with early-stage dementia or Alzheimer's disease: An integrative review. *Research in Gerontological Nursing*. 2019;12(5):259-268. Nivå 1

46. Vossius C, Selbæk G, Benth JŠ, Wimo A, Engedal K, Kirkevold Ø, Rokstad AMM.

Cost analysis of day care centres in Norway. *PLoS One*, 8;14(8):e0219568. Nivå 1

KONFERANSEBIDRAG FORSKNING - FAGLIG PRESENTASJON

1. **Aakre JA, Ballard C, Årsland D, Corbett A, Hampshire A, Brooker H, Testad I.** Correlates and prevalence of self-reported sleep and cognitive performance in a large online community-based aging cohort. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019*.
2. **Bergland AK, Sønnesyn H, Aarsland D.** Lipid profile and cognition in older adults with prodromal dementia. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019*.
3. **Borejko O, Ballard C, Aarsland D.** Alzheimer's disease cerebrospinal fluid biomarkers effect on cognitive changes in Lewy Body dementias. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019*.

4. **Borda MG, Brønnick K, Reyes-Ortiz CA, Alves G, Vik-Mo AO, Oppedal K, Cano-Gutierrez C, Aarsland D.** Neuropsychiatric symptoms at diagnosis correlate with disability trajectories among people living with Alzheimer's disease and Dementia with Lewy Bodies. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019.*
5. **Borda MG, Aarsland D, Melvaer Giil L, Kolbjørn B, Alves G, Oppedal K, Soennesyn H, Osland Vik-Mo A.** Neuropsychiatric symptoms at diagnosis correlate with disability trajectories among people living with Alzheimer's disease dementia and Lewy body dementia. *Lewy body dementia international congress. Las Vegas, United states of America. June 2019*
6. **Holteng LBA., Langeland I., Testad I.** FOKUS. *Care Home Research Network Conference. King's College London 05/2019*
7. **Holteng LB, Testad I.** Improving nutrition and quality of life through person-centered nutrition and use of texture-modified food in people living with dementia and dysphagia in care homes - A quasi-experimental study. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019.*
8. **Kajander M, Ballard C, Næss H, Testad I.** An observational study of a 12-week Health Promotion Course for people with early-stage dementia. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019.*
9. **Khalifa K, Bergland AK, Aarsland D, Holteng LB, Soennesyn H.** Effects of AnthoCyanins In people at risk for Dementia (ACID). A randomised, 24-week parallel-group placebo-controlled multicenter STUDY (Phase 2). Study Protocol and current status. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019.*
10. **Testad I, Kajander M, Henriksen AT, Vagle V, Meling M, Gjestsen MT.** Health Promotion for people with early-stage dementia: A quasi-experimental study. *GSA 2019 Annual Scientific Meeting, November 13-17, 2019, Austin, Texas*
11. **Østerhus RD, Kjosavik S, Aarsland D.** Hospitalisation in Patients with Alzheimer's Disease and Lewy Body Dementia. *International Collaboration Meeting – University of Exeter & SESAM, Stavanger 05/2019.*